Dechra Pharmaceuticals

Dechra Pharmaceuticals plc. Is a pharmaceutical company that develops, manufactures and markets veterinary pharmaceutical products worldwide. Founded in 1997 by way of a buyout from Lloyds Chemist. The company has operations in Europe as well as North America in addition to running a pharmaceutical research center.

The company’s pipeline of pharmaceuticals is made up of products for endocrinology, dermatology analgesia, and other critical care products for dogs and cats and poultry vaccines. The company bought Danish veterinary product business VetXX for £62 million in 2007. In 2013, it divested its veterinary service business to Patterson Companies for £87.5 million.

Dechra Pharmaceuticals plc. is also engaged in the production and distribution of pet nutrition products. It also develops manufactures and regulates crop production.

Dechra Pharmaceuticals plc. went public in 2000 and was listed on the London Stock Exchange.

Latest Dechra Pharmaceuticals News

FTSE 100 Index – An Overview Of Friday, October 18th, 2019

Following yesterday’s announcement that Brexit deal has been finalized in the European Union Summit (EU summit), the celebration in the FTSE 100 index was quite evident. The market made a daily high of 7,237.78. While significant gains were still lost...

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.